MwanzoGS71 • FRA
add
GSK plc
Bei iliyotangulia
€ 17.96
Bei za siku
€ 17.71 - € 18.02
Bei za mwaka
€ 15.70 - € 21.57
Thamani ya kampuni katika soko
79.73B USD
Wastani wa hisa zilizouzwa
elfu 1.26
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
LON
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (GBP) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 7.88B | 9.84% |
Matumizi ya uendeshaji wa biashara | 3.61B | 10.07% |
Mapato halisi | 1.17B | -27.77% |
Kiwango cha faida halisi | 14.88 | -34.22% |
Mapato kwa kila hisa | 1.11 | 187.26% |
EBITDA | 2.85B | 16.30% |
Asilimia ya kodi ya mapato | 12.78% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (GBP) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 2.98B | -54.14% |
Jumla ya mali | 58.07B | -2.35% |
Jumla ya dhima | 44.30B | -6.35% |
Jumla ya hisa | 13.77B | — |
hisa zilizosalia | 4.08B | — |
Uwiano wa bei na thamani | 5.10 | — |
Faida inayotokana na mali | 9.50% | — |
Faida inayotokana mtaji | 17.95% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (GBP) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 1.17B | -27.77% |
Pesa kutokana na shughuli | 1.11B | -14.84% |
Pesa kutokana na uwekezaji | 770.00M | 179.88% |
Pesa kutokana na ufadhili | -1.58B | -5,209.68% |
Mabadiliko halisi ya pesa taslimu | 291.00M | -8.20% |
Mtiririko huru wa pesa | 551.62M | -22.66% |
Kuhusu
GSK plc is a British multinational pharmaceutical and biotechnology company with headquarters in London. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.
GSK is the tenth largest pharmaceutical company and No. 294 on the 2022 Fortune Global 500, ranked behind other pharmaceutical companies China Resources, Sinopharm, Johnson & Johnson, Pfizer, Roche, AbbVie, Novartis, Bayer, and Merck Sharp & Dohme.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. As of February 2024, it had a market capitalisation of £69 billion, the eighth largest on the London Stock Exchange.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Legacy products developed at GSK include several listed in the World Health Organization's List of Essential Medicines, such as amoxicillin, mercaptopurine, pyrimethamine and zidovudine. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
27 Des 2000
Tovuti
Wafanyakazi
70,212
